Breast cancer cells preferentially metastasise to the skeleton, owing, in part, to the fertile environment provided by bone. Increased bone turnover releases growth factors that promote tumour cell growth. In turn, tumour cells release factors that stimulate further bone turnover, resulting in a vicious cycle of metastasis growth and bone destruction. The RANK-RANK ligand (RANKL) pathway plays a key role in this cycle, and inhibition of RANKL using the fully-human monoclonal antibody denosumab, has demonstrated efficacy in delaying skeletal complications associated with bone metastases in three phase 3 trials. Preclinical studies suggest that the RANKL pathway also plays a role in breast cancer tumourigenesis and migration to bone. In a subgroup analysis of the negative Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) trial, the bisphosphonate zoledronic acid showed potential for improving survival in patients who were postmenopausal; however, a prospective study in this patient population is required to validate this observation. Ongoing trials are examining whether adjuvant blockade of the RANKL pathway using denosumab can prevent disease recurrence in patients with high-risk breast cancer. These are building on analogous studies that have shown that denosumab improves bone metastasis-free survival in prostate cancer and suggested that it confers an overall survival benefit in non-small-cell lung cancer.
References
[1]
Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, 12, 6243–6249, doi:10.1158/1078-0432.CCR-06-0931.
[2]
Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165–176, doi:10.1053/ctrv.2000.0210.
[3]
DePuy, V.; Anstrom, K.J.; Castel, L.D.; Schulman, K.A.; Weinfurt, K.P.; Saad, F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support. Care Cancer 2007, 15, 869–876, doi:10.1007/s00520-006-0203-x.
[4]
Sathiakumar, N.; Delzell, E.; Morrisey, M.A.; Falkson, C.; Yong, M.; Chia, V.; Blackburn, J.; Arora, T.; Brill, I.; Kilgore, M.L. Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of U. S. medicare beneficiaries, 1999–2006. Breast Cancer Res. Treat. 2012, 131, 231–238, doi:10.1007/s10549-011-1721-x.
[5]
Costa, L.; Badia, X.; Chow, E.; Lipton, A.; Wardley, A. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support. Care Cancer 2008, 16, 879–889, doi:10.1007/s00520-008-0418-0.
[6]
Briasoulis, E.; Karavasilis, V.; Kostadima, L.; Ignatiadis, M.; Fountzilas, G.; Pavlidis, N. Metastatic breast carcinoma confined to bone: Portrait of a clinical entity. Cancer 2004, 101, 1524–1528, doi:10.1002/cncr.20545.
[7]
Wang, C.Y.; Wu, G.Y.; Shen, M.J.; Cui, K.W.; Shen, Y. Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol. Lett. 2013, 5, 391–397.
[8]
Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563–572, doi:10.1038/nrc865.
[9]
Luzzi, K.J.; MacDonald, I.C.; Schmidt, E.E.; Kerkvliet, N.; Morris, V.L.; Chambers, A.F.; Groom, A.C. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 1998, 153, 865–873, doi:10.1016/S0002-9440(10)65628-3.
[10]
Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133, 571–573, doi:10.1016/S0140-6736(00)49915-0.
[11]
Kingsley, L.A.; Fournier, P.G.; Chirgwin, J.M.; Guise, T.A. Molecular biology of bone metastasis. Mol. Cancer Ther. 2007, 6, 2609–2617, doi:10.1158/1535-7163.MCT-07-0234.
[12]
Roodman, G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004, 350, 1655–1664, doi:10.1056/NEJMra030831.
[13]
Dougall, W.C. Molecular pathways: Osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin. Cancer Res. 2012, 18, 326–335, doi:10.1158/1078-0432.CCR-10-2507.
Guise, T.A.; Yin, J.J.; Taylor, S.D.; Kumagai, Y.; Dallas, M.; Boyce, B.F.; Yoneda, T.; Mundy, G.R. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 1996, 98, 1544–1549, doi:10.1172/JCI118947.
[16]
Karaplis, A.C.; Goltzman, D. PTH and PTHrP effects on the skeleton. Rev. Endocr. Metab. Disord. 2000, 1, 331–341, doi:10.1023/A:1026526703898.
[17]
Canon, J.R.; Roudier, M.; Bryant, R.; Morony, S.; Stolina, M.; Kostenuik, P.J.; Dougall, W.C. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 2008, 25, 119–129, doi:10.1007/s10585-007-9127-1.
[18]
Zheng, Y.; Zhou, H.; Modzelewski, J.R.; Kalak, R.; Blair, J.M.; Seibel, M.J.; Dunstan, C.R. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res. 2007, 67, 9542–9548, doi:10.1158/0008-5472.CAN-07-1046.
[19]
Stopeck, A.T.; Lipton, A.; Body, J.J.; Steger, G.G.; Tonkin, K.; de Boer, R.; Lichinitser, M.; Fujiwara, Y.; Yardley, D.; Viniegra, M.; et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 2010, 28, 5132–5139, doi:10.1200/JCO.2010.29.7101.
[20]
Fizazi, K.; Carducci, M.; Smith, M.; Dami？o, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011, 377, 813–822, doi:10.1016/S0140-6736(10)62344-6.
[21]
Henry, D.H.; Costa, L.; Goldwasser, F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti, G.V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 2011, 29, 1125–1132, doi:10.1200/JCO.2010.31.3304.
[22]
Lipton, A.; Fizazi, K.; Stopeck, A.T.; Henry, D.H.; Brown, J.E.; Yardley, D.A.; Richardson, G.E.; Siena, S.; Maroto, P.; Clemens, M.; et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 2012, 48, 3082–3092, doi:10.1016/j.ejca.2012.08.002.
[23]
Cleeland, C.S.; Body, J.J.; Stopeck, A.; von Moos, R.; Fallowfield, L.; Mathias, S.D.; Patrick, D.L.; Clemons, M.; Tonkin, K.; Masuda, N.; et al. Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013, 119, 832–838, doi:10.1002/cncr.27789.
[24]
Martin, M.; Bell, R.; Bourgeois, H.; Brufsky, A.; Diel, I.; Eniu, A.; Fallowfield, L.; Fujiwara, Y.; Jassem, J.; Paterson, A.H.; et al. Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid. Clin. Cancer Res. 2012, 18, 4841–4849, doi:10.1158/1078-0432.CCR-11-3310.
[25]
Kearns, A.E.; Khosla, S.; Kostenuik, P.J. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29, 155–192.
[26]
Beleut, M.; Rajaram, R.D.; Caikovski, M.; Ayyanan, A.; Germano, D.; Choi, Y.; Schneider, P.; Brisken, C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. USA 2010, 107, 2989–2994, doi:10.1073/pnas.0915148107.
[27]
Tanos, T.; Sflomos, G.; Echeverria, P.C.; Ayyanan, A.; Gutierrez, M.; Delaloye, J.F.; Raffoul, W.; Fiche, M.; Dougall, W.; Schneider, P.; et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3005654.
[28]
Fata, J.E.; Kong, Y.Y.; Li, J.; Sasaki, T.; Irie-Sasaki, J.; Moorehead, R.A.; Elliott, R.; Scully, S.; Voura, E.B.; Lacey, D.L.; et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103, 41–50, doi:10.1016/S0092-8674(00)00103-3.
[29]
Fernandez-Valdivia, R.; Lydon, J.P. From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol. Cell. Endocrinol. 2012, 357, 91–100, doi:10.1016/j.mce.2011.09.030.
Baron, R.; Ferrari, S.; Russell, R.G. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 2011, 48, 677–692, doi:10.1016/j.bone.2010.11.020.
[34]
Santini, D.; Schiavon, G.; Vincenzi, B.; Gaeta, L.; Pantano, F.; Russo, A.; Ortega, C.; Porta, C.; Galluzzo, S.; Armento, G.; et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011, 6, e19234, doi:10.1371/journal.pone.0019234.
[35]
Palafox, M.; Ferrer, I.; Pellegrini, P.; Vila, S.; Hernandez-Ortega, S.; Urruticoechea, A.; Climent, F.; Soler, M.T.; Munoz, P.; Vinals, F.; et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res. 2012, 72, 2879–2888, doi:10.1158/0008-5472.CAN-12-0044.
[36]
Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Stoeger, H.; Dubsky, P.; Jakesz, R.; Singer, C.; Eidtmann, H.; Fesl, C.; Eiermann, W.; et al. Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor—Positive early breast cancer. Cancer Res. 2011, 71, doi:10.1158/0008-5472.SABCS11-S1-2.
[37]
Coleman, R.E.; Marshall, H.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston, S.J.; Grieve, R.J.; Barrett-Lee, P.J.; et al. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 2011, 365, 1396–1405, doi:10.1056/NEJMoa1105195.
[38]
Coleman, R.; Bundred, N.; de Boer, R.; Llombarto, A.; Campbell, I.; Neven, P.; Barrios, C.; Dias, R.; Miller, J.; Brufsky, A. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Cancer Res. 2009, 69, doi:10.1158/0008-5472.SABCS-09-4082.
[39]
Coleman, R.; de Boer, R.; Eidtmann, H.; Llombart, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Sleeboom, H.P.; Forbes, J.; Barrios, C.; et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann. Oncol. 2013, 24, 398–405, doi:10.1093/annonc/mds277.
[40]
Wong, M.H.F.; Stockler, M.R.; Pavlakis, N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev. 2012, 15, doi:10.1002/14651858.CD003474.pub3.
[41]
Paterson, A.H.; Anderson, S.J.; Lembersky, B.C.; Fehrenbacher, L.; Falkson, C.I.; King, K.M.; Weir, L.M.; Brufsky, A.M.; Dakhil, S.; Lad, T.; et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012, 13, 734–742, doi:10.1016/S1470-2045(12)70226-7.
[42]
Saarto, T.; Blomqvist, C.; Virkkunen, P.; Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: Five-year results of a randomized controlled trial. J. Clin. Oncol. 2001, 19, 10–17.
[43]
Hadji, P.; Coleman, R.; Gnant, M.; Green, J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann. Oncol. 2012, 23, 2782–2790, doi:10.1093/annonc/mds169.
[44]
Steinman, R.A.; Brufsky, A.M.; Oesterreich, S. Zoledronic acid effectiveness against breast cancer metastases—A role for estrogen in the microenvironment? Breast Cancer Res. 2012, 14, 213, doi:10.1186/bcr3223.
[45]
Azim, H.A., Jr.; Michiels, S.; Bedard, P.L.; Singhal, S.K.; Criscitiello, C.; Ignatiadis, M.; Haibe-Kains, B.; Piccart, M.J.; Sotiriou, C.; Loi, S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin. Cancer Res. 2012, 18, 1341–1351, doi:10.1158/1078-0432.CCR-11-2599.
[46]
Smith, M.R.; Saad, F.; Coleman, R.; Shore, N.; Fizazi, K.; Tombal, B.; Miller, K.; Sieber, P.; Karsh, L.; Damiao, R.; et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379, 39–46, doi:10.1016/S0140-6736(11)61226-9.
Scagliotti, G.V.; Hirsh, V.; Siena, S.; Henry, D.H.; Woll, P.J.; Manegold, C.; Solal-Celigny, P.; Rodriguez, G.; Krzakowski, M.; Mehta, N.D.; et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J. Thorac. Oncol. 2012, 7, 1823–1829, doi:10.1097/JTO.0b013e31826aec2b.
[49]
European Association of Urology (EAU) Press release, 19 March 2013. Zoledronic acid does not prevent bone metastases in high-risk PCa patients. Available online: http://www.eaumilan2013.org/press/press-releases/ (accessed on 28 May 2013).
[50]
Scagliotti, G.V.; Kosmidis, P.; de Marinis, F.; Schreurs, A.J.; Albert, I.; Engel-Riedel, W.; Schallier, D.; Barbera, S.; Kuo, H.P.; Sallo, V.; et al. Zoledronic acid in patients with stage IIIA/B NSCLC: Results of a randomized, phase III study. Ann. Oncol. 2012, 23, 2082–2087, doi:10.1093/annonc/mds128.
[51]
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE). Available online: http://www.clinicaltrials.gov/ct2/show/NCT01077154?term=d-care&rank=1 (accessed on 20 April 2013).
[52]
Coleman, R.E.; Barrios, C.; Bell, R.; Finkelstein, D.M.; Iwata, H.; Martin, M.; Braun, A.; Ke, C.; Maniar, T.; Goss, P.E. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An in progress, phase 3 clinical trial. Ann. Oncol. 2012, 23, 95–115.
[53]
Study to Determine Treatment Effects of Denosumab in Patients with Breast Cancer Receiving Aromatase Inhibitor Therapy. Available online: http://clinicaltrials.gov/show/NCT00556374 (accessed on 20 April 2013).
